Novo Nordisk flags Cagrilintide promise in hunt for next obesity drug US$ 28.98 Min. order: 1 piece ★★★★★ 4.8 (140 reviews) Sold : Login>>
Novo Nordisk's CagriSema trial deals blow in obesity drug battle with Eli Lilly US$ 21.95 Min. order: 1 piece ★★★★★ 5.0 (143 reviews) Sold : Login>>
VisualAbstract: Cagrilintide-Semaglutide is Effective for Weight Loss in Adults with Overweight or Obesity and Type 2 Diabetes US$ 25.71 Min. order: 1 piece ★★★★★ 4.2 (172 reviews) Sold : Login>>
Novo Nordisk to initiate study assessing CagriSema vs Tirzepatide US$ 22.60 Min. order: 1 piece ★★★★★ 4.7 (273 reviews) Sold : Login>>
Novo Nordisk files for FDA approval for CagriSema, the first once-weekly combination of GLP‑1 and amylin analogues US$ 23.01 Min. order: 1 piece ★★★★★ 5.0 (63 reviews) Sold : Login>>
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial US$ 22.52 Min. order: 1 piece ★★★★★ 4.5 (291 reviews) Sold : Login>>